SynthesisFrontiers in pharmacology2025
Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials.
Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Adjunctive berberine for schizophrenia with metabolic syndrome: a systematic review and meta-analysis.Frontiers in psychiatry · 2026Pooled it
- The effect of barberry supplementation on components of metabolic syndrome: a grade assessment systematic review and meta-analysis of randomized controlled trials.Journal of health, population, and nutrition · 2025Pooled it
- Trial
- Efficacy and safety ofFrontiers in pharmacology · 2025Trial
- Dietary Bioactive Compounds: Cellular Sensory Pathways, Microbial Partners, and Clinical Realities.Nutrients · 2026Review
- Berberine and its derivatives as candidate modulators of immunosenescence: a critical evaluation.Biogerontology · 2026Review
- Berberine-associated lipid-inflammatory regulation in atherosclerosis: an integrative transcriptomic, single-cell, and in vivo study.Functional & integrative genomics · 2026Article
- Non-Pharmacological Strategies in Atherosclerotic Cardiovascular Disease: From Molecular Mechanisms to Clinical Integration.Biomedicines · 2026Review
- Microbiome-Directed Bioactive Strategies in Skin Aging: Mechanistic Insights and Precision Nanocarrier Delivery Approaches.Molecules (Basel, Switzerland) · 2026Review
- Natural Products as Nutritional Supplements in Human Disease Prevention and Management: From Molecular Mechanisms to Clinical Translation.Nutrients · 2026Review
- Natural Bioactive Compounds Targeting Gut Barrier Integrity and Metabolic Endotoxemia in Cardiometabolic Disease: Mechanistic Insights and Translational Perspectives.Molecules (Basel, Switzerland) · 2026Review
- Obesity and Natural Products: Mechanisms, Therapeutic Potential, and Future Directions.Food science & nutrition · 2026Review
- Berberine in oral diseases: molecular mechanisms and therapeutic implications.Frontiers in pharmacology · 2026Review
- Molecular mechanisms and preclinical evidence of natural products in diabetic osteoporosis: a review.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolic syndrome (MetS) is a prevalent metabolic disease that significantly increases the risk of type 2 diabetes, cardiovascular diseases, and overall mortality. Current medications have limited effects on the various components of MetS. Berberine has demonstrated unique comprehensive therapeutic benefits for MetS, but its efficacy remains uncertain. Objective: To comprehensively evaluate the efficacy and safety of berberine on MetS indicators. Methods: Our study provides a comprehensive evaluation of the efficacy and safety of berberine for MetS components through systematic review and meta-analysis, from the aspects of study characteristics, risk of bias, meta-analysis, sensitivity analysis, meta-regression, and publication bias. Results: The results indicate that berberine significantly reduces triglycerides (TG) (WMD: -0.367 mmol/L; 95% CI: -0.560 to -0.175; Conclusion: Berberine significantly improves glucose and lipid metabolism and has notable effects on components of MetS, including TG, FPG, and WC, with a favorable safety profile. It may serve as a beneficial supplement. Meanwhile, more high-quality, rigorously designed randomized controlled trials are needed in the future to provide stronger evidence. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024588614.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.